A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
← catalyst calendarNCT06882785 · readout in 765 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
250estimated
Sites
56
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-10 | actual | When the study began enrolling |
| Primary completion | 2028-09-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-08-23 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Schizophrenia
Interventions
- Drug: KarXT — also filed as BMS-986510
- Other: Placebo
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in Positive and Negative Syndrome Scale (PANSS) total score
measured At week 5
Number of participants with treatment-emergent adverse events (TEAEs)
measured At Week 52 from OLE baseline
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed